PuSH - Publication Server of Helmholtz Zentrum München: MVA-HBVac-A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Kosinska, A. ; Kächele, M. ; Kerth, H.A. ; Mück-Häusl, M. ; Ates Öz, E. ; Gültan, M. ; Hansen-Palmus, L. ; Sacherl, J. ; Ko, C. ; Festag, J. ; Lehmann, M.H.* ; Mogler, C.* ; Steiger, K.* ; Knolle, P.A.* ; Bauer, T. ; Volz, A.K.* ; Protzer, U.

MVA-HBVac-A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination.

Mol. Ther. Nucleic Acids 36:102641 (2025)

Publ. Version/Full Text

Research data

DOI

PMC

	Open Access Gold

Abstract
Metrics
Extra information

Therapeutic vaccination holds the promise to cure chronic hepatitis B virus (HBV) infection. We hypothesize that B cell, CD4, and CD8 T cell responses are necessary to overcome HBV-specific immune tolerance in chronic infection because they accompany the rare, spontaneous resolution of chronic HBV infection. Therefore, we designed the heterologous prime-boost vaccine TherVacB in which virus-like particle vaccination stimulates B and helper CD4 T cells and primes cytotoxic effector CD8 T cells and a vector boost expands the T cell response. Here, we report the generation and characterization of a novel modified vaccinia virus Ankara (MVA)-based vector, MVA-HBVac, capable of inducing strong and multi-specific T cell responses against the immunodominant epitopes of four different viral proteins covering >95% of HBV strains circulating worldwide. When MVA-HBVac was administered after a prime with adjuvanted hepatitis B S- and core-antigens forming virus-like particles, it activated strong HBV-specific CD4 and CD8 T cell responses against the major HBV antigens in vivo in naive and HBV carrier mice. This induced a sustained antiviral effect against different, clinically relevant HBV genotypes. Our data showed that the TherVacB regimen employing the novel, pan-genotypic MVA-HBVac vector could overcome HBV-specific immune tolerance and lead to the initiation of clinical trials evaluating the therapeutic vaccine.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Keywords Hbv ; Mt: Delivery Strategies ; Mva ; Thervacb ; Chronic Hepatitis B ; Heterologous Prime Boost ; Therapeutic Vaccination ; Viral Vector; Boost Vaccination; Surface-antigen; Viral Clearance; X Protein; Cells; Immunogenicity; Regimen

ISSN (print) / ISBN 2162-2531

e-ISSN 2162-2531

Journal Molecular therapy - Nucleic Acids

Quellenangaben Volume: 36, Issue: 3, Article Number: 102641

Publisher Elsevier

Publishing Place New York, NY

Reviewing status Peer reviewed

Institute(s) Institute of Virology (VIRO)

Grants German Center for Infection Research (DZIF)
C-NATM - Cluster for Nucleic Acid Therapeutics Munich - Clusters4Future initiative
German Ministry for Education and Research (BMBF) via the TherVacB PLUS project
German Center for Infection Research via project TTU 05.803 HBV Cure
EU Horizon 2020 consortium TherVacB
PoC initiative by the Helmholtz and Fraunhofer Associations
German Research Foundation via TRR179